Wait a second. J&J is back in the bidding for Actelion, elbowing Sanofi aside
One minute reporters for Bloomberg and Reuters are telling you that the Sanofi $SNY takeover talks with Actelion $ATLN are progressing nicely, and the next minute Sanofi is out and J&J is back in.
Just seven days after J&J formally said it was pushing away from the deal table and dropping an effort to buy Actelion, the pharma giant now has entered into “exclusive negotiations” with the Swiss biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.